For patients with early-stage lung adenocarcinomas, the histological pattern of the tumor predicts the risk of recurrence and might help guide surgical decisions.
For patients with early-stage lung adenocarcinomas, the histological pattern of the tumor predicts the risk of recurrence and might help guide surgical decisions, researchers reported.
In a retrospective study, recurrence was significantly increased among patients who had a tumor resection if 5% or more of the cancer had micropapillary morphology, according to Prasad Adusumilli, MD, of Memorial Sloan-Kettering Cancer Center in New York City, and colleagues.
Knowing what proportion of the tumor has micropapillary morphology could help doctors and patients decide whether to resect the tumor or to remove the lobe, Adusumilli and colleagues reported in the Aug. 20 issue of the Journal of the National Cancer Institute.
The finding is likely to "carry increasing importance" in the next few years as the number of cases of early-stage lung cancer rises as a result of the National Lung Screening Trial, the researchers argued.
Read the full story here: http://bit.ly/1cKwjtc
Source: Med Page Today
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More